This application is related to co-pending, commonly assigned Siejko et al. U.S. patent application Ser. No. 10/307,896, entitled “PHONOCARDIOGRAPHIC IMAGE-BASED ATRIOVENTRICULAR DELAY OPTIMIZATION,” filed Dec. 2, 2002, now issued as U.S. Pat. No. 7,123,962, which is hereby incorporated by reference.
This document relates generally to cardiac rhythm management systems and particularly, but not by way of limitation, to such a system sensing heart sounds for monitoring, diagnosis, and therapy control.
A heart is the center of a person's circulatory system. It includes a complex electro-mechanical system performing two major pumping functions. The left portions of the heart, including the left atrium and the left ventricle, draw oxygenated blood from the lungs and pump it to the organs of the body to provide the organs with their metabolic needs for oxygen. The right portions of the heart, including the right atrium and the right ventricle, draw deoxygenated blood from the organs and pump it into the lungs where the blood gets oxygenated. These mechanical pumping functions are accomplished by contractions of the myocardium (heart muscles). In a normal heart, the sinus node, the heart's natural pacemaker, generates electrical signals, called action potentials, that propagate through an electrical conduction system to various regions of the heart to excite myocardial tissues in these regions. Coordinated delays in the propagations of the action potentials in a normal electrical conduction system cause the various regions of the heart to contract in synchrony such that the pumping functions are performed efficiently. Thus, the normal pumping functions of the heart, indicated by hemodynamic performance, require a normal electrical system to generate the action potentials and deliver them to designated portions of the myocardium with proper timing, a normal myocardium capable of contracting with sufficient strength, and a normal electro-mechanical association such that all regions of the heart are excitable by the action potentials.
The function of the electrical system is indicated by electrocardiography (ECG) with at least two electrodes placed in or about the heart to sense the action potentials. When the heart beats irregularly or otherwise abnormally, one or more ECG signals indicate that contractions at various cardiac regions are chaotic and unsynchronized. Such conditions are known as cardiac arrhythmias. Cardiac arrhythmias result in a reduced pumping efficiency of the heart, and hence, diminished blood circulation. Examples of such arrhythmias include bradyarrhythmias, that is, hearts that beat too slowly or irregularly, and tachyarrhythmias, that is, hearts that beat too quickly. A patient may also suffer from weakened contraction strength related to deterioration of the myocardium. This further reduces the pumping efficiency. For example, a heart failure patient suffers from an abnormal electrical conduction system with excessive conduction delays and deteriorated heart muscles that result in asynchronous and weak heart contractions, and hence, reduced pumping efficiency, or poor hemodynamic performance. Thus, in addition to ECG, the function of the mechanical system and the electro-mechanical association need to be measured to assess the overall pumping performance of the heart.
Characteristics of heart sounds are known to be indicative of various mechanical properties and activities of the heart. Measurements performed with synchronously recorded ECG and heart sounds provide for quantitative indications of the electro-mechanical association. For example, amplitudes of the third heart sound (S3) and fourth heart sound (S4) are related to filling pressures of the left ventricle during diastole. Fundamental frequencies of S3 and S4 are related to ventricular stiffness and dimension. Chronic changes in S3 amplitude is correlated to left ventricular chamber stiffness and degree of restrictive filling. Change in the interval between atrial contraction and S4 is correlated to the changes in left ventricular end of diastolic pressure. Such parameters, being correlated to the heart's mechanical properties and electromechanical association, quantitatively indicate abnormal cardiac conditions, including degrees of severity, and need of appropriate therapies.
For these and other reasons, there is a need for a system providing for cardiac therapy based on parameters related to heart sounds.
A cardiac rhythm management system provides for ambulatory monitoring of hemodynamic performance based on quantitative measurements of heart sound related parameters for diagnostic and therapeutic purposes. Monitoring of such heart sound related parameters allows the cardiac rhythm management system to determine a need for delivering a therapy and/or therapy parameter adjustments based on conditions of a heart. This monitoring also allows a physician to observe or assess the hemodynamic performance for diagnosing and making therapeutic decisions. Because the conditions of the heart may fluctuate and may deteriorate significantly between physician visits, the ambulatory monitoring, performed on a continuous or periodic basis, ensures a prompt response by the cardiac rhythm management system that may save a life, prevent hospitalization, or prevent further deterioration of the heart.
In one embodiment, a system includes an acoustic sensor, a cardiac sensing circuit, a heart sound detector, a parameter generator, a processor, and a therapy circuit. The acoustic sensor senses an acoustic energy and produces an acoustic sensor signal indicative heart sounds. The cardiac sensing circuit senses a cardiac signal indicative of cardiac electrical events. The heart sound detector detects selected heart sounds based on the acoustic sensor signal and the cardiac signal. The parameter generator generates values of at least one predetermined parameter related to the selected heart sounds. The processor includes a trending analyzer that produces and analyzes at least one trend related to the selected heart sounds based on the values of the predetermined parameter. The therapy circuit delivers cardiac therapy with at least one therapy parameter determined based on the trend.
In another embodiment, an acoustic energy is sensed to produce an acoustic sensor signal indicative heart sounds. One or more cardiac signals indicative of cardiac electrical events are also sensed. Selected heart sounds are detected. Parameter values related to the selected heart sounds and selected cardiac electrical events are generated. Selected parameter values, which are associated with one or more types of the selected heart sounds, are analyzed to produce at least one trend. A therapy, with at least one parameter determined based on the trend, is delivered.
In yet another embodiment, a cardiac rhythm management system includes an implantable device. The implantable device includes an acoustic sensor, a cardiac sensing circuit, a gating module, a heart sound detector, a measurement module, and a therapy circuit. The acoustic sensor senses an acoustic energy to produce an acoustic sensor signal indicative heart sounds. The cardiac sensing circuit senses at least one cardiac signal indicative of cardiac electrical events. The gating module generates heart sound detection windows each timed for detection of one of selected heart sounds based on a time of occurrence of one of selected cardiac electrical events. The heart sound detector detects the selected heart sounds. The measurement module generates parameter values related to the selected heart sounds. The therapy circuit delivers a therapy based on the parameter values.
This summary is intended not to limit the claimed subject matter, and the scope of the invention is defined by attached claims and their equivalents.
In the drawings, which are not necessarily drawn to scale, like numerals describe similar components throughout the several views. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
In the following detailed description, reference is made to the accompanying drawings that form a part hereof, and in which is shown, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.
This document discusses, among other things, a cardiac rhythm management system monitoring heart sounds indicative of a heart's mechanical events related to the heart's pumping functions and hemodynamic performance to allow, among other things, diagnosis of cardiac conditions and selection of therapies treating the cardiac conditions. The cardiac rhythm management systems include systems having, for example, pacemakers, cardioverter/defibrillators, pacemaker/defibrillators, and cardiac resynchronization therapy (CRT) devices. One specific example of a cardiac rhythm management system that monitors and analyses heart sounds is described in co-pending, commonly assigned Siejko et al. U.S. patent application Ser. No. 10/307,896, entitled “PHONOCARDIOGRAPHIC IMAGE-BASED ATRIOVENTRICULAR DELAY OPTIMIZATION,” filed Dec. 2, 2002, now issued as U.S. Pat. No. 7,123,962, which is hereby incorporated by reference in its entirety. However, it is to be understood that the present methods and apparatuses may be employed in other types of medical devices, including, but not being limited to, drug delivery systems and various types of cardiac monitoring devices.
Known and studied heart sounds include the “first heart sound” or S1, the “second heart sound” or S2, the “third heart sound” or S3, the “fourth heart sound” or S4, and their various sub-components. S1 is known to be indicative of, among other things, mitral valve closure, tricuspid valve closure, and aortic valve opening. S2 is known to be indicative of, among other things, aortic valve closure and pulmonary valve closure. S3 is known to be a ventricular diastolic filling sound often indicative of certain pathological conditions including heart failure. S4 is known to be a ventricular diastolic filling sound resulted from atrial contraction and is usually indicative of pathological conditions. The term “heart sound” hereinafter refers to any heart sound (e.g., S1) and any components thereof (e.g., M1 component of S1, indicative of Mitral valve closure).
Throughout this document, “heart sound” includes audible and inaudible mechanical vibrations caused by cardiac activity that can be sensed with an accelerometer. Accordingly, the scope of “acoustic energy” in this document extends to energies associated with such mechanical vibrations.
Throughout this document, “user” refers to a physician or other caregiver who examines and/or treats a patient using one or more of the methods and apparatuses reported in the present document. Unless noted otherwise, S1, S2, S3, and S4 refer to the first, second, third, and fourth heart sounds, respectively, as a heart sound type, or as one or more occurrences of the corresponding type heart sounds, depending on the context.
Acoustic sensor 110 senses an acoustic energy or mechanical vibration energy related to cardiac mechanical activities and converts the acoustic energy to an acoustic sensor signal indicative of heart sounds. The acoustic sensor signal is an electrical signal indicative of timing, strength, and frequency characteristics related to the heart sounds. Acoustic sensor 110 is disposed in a heart, or near the heart in a location where the acoustic energy related to the cardiac mechanical activities can be sensed. In one embodiment, acoustic sensor 110 includes an accelerometer disposed in or near a heart. In another embodiment, acoustic sensor 110 includes a microphone disposed in or near a heart.
Sensor interface module 120 has a signal input connected to the output of acoustic sensor 110 to receive the acoustic sensor signal. It processes the acoustic sensor signal to prepare for detection of selected type heart sounds. The selected type heart sounds are heart sounds selected for a purpose of monitoring a patient's hemodynamic performance indicated by the measurable characteristics of these heart sounds. In one specific embodiment, the selected type heart sounds includes S3 and S4, which are indicative of ventricular diastolic hemodynamic performance. Sensor interface module includes a signal conditioning circuit 122, a digitizer 124, and a digital filter 126. Signal conditioning circuit 122 receives the acoustic sensor signal as an analog signal from acoustic sensor 110, and performs initial conditioning of the acoustic sensor signal. In one embodiment, signal conditioning circuit 122 improves the signal-to-noise ratio of the acoustic sensor signal. It includes an amplifier and a filter to amplify the acoustic sensor signal while reducing the noise therein. In one embodiment, the filter is an analog filter that substantially reduces amplitudes of noises that are not within the frequency spectrum of the selected type heart sounds. In another embodiment, the filter substantially reduces amplitudes of noises as well as components of the acoustic sensor signal that are outside of the frequency range of the selected type heart sounds. Digitizer 124 digitizes the filtered acoustic sensor signal by sampling it at a predetermined rate. In one embodiment, the sampling rate is programmable and determined based on known frequency characteristics of the heart sounds to be detected. In one embodiment, digitizer 124 samples the acoustic sensor signal only during predetermined periods of time where the selected type heart sounds are most likely to be present. This saves electrical energy required for processing the acoustic sensor signal and/or allows a higher resolution of the digitized acoustic sensor signal without substantially increasing the electrical energy required for processing. Energy conservation is of particular importance when system 100 is a totally implantable system or includes implantable components. Digital filter 126 substantially reduces amplitudes for all components of the acoustic sensor signal except the selected type heart sounds, which are to be detected by heart sound detector 130, thereby enhancing the indications of the selected type heart sounds. In one embodiment, digital filter 126 includes a band-pass filter having cutoff frequencies determined based on the frequency spectrum of the selected type heart sounds. It is to be understood, however, that the cutoff frequencies are dependent on the purpose of detection and need not cover exactly the known spectrum of particular heart sounds. In one specific embodiment, digital filter 126 is band-pass filter having a low cutoff frequency in the range of 5 to 20 Hz and a high cutoff frequency in the range of 30 to 120 Hz selected for the purpose of detecting S3 and S4. One example of a suitable pass band for digital filter 126 for detection of S3 and S4 for monitoring ventricular diastolic hemodynamics includes a low cutoff frequency of 10 Hz and a high cutoff frequency of 60 Hz. In one specific embodiment, digital filter 126 is an envelope detector type filter. In one embodiment, digital filter 126 is a programmable digital filter in which at least one of the cutoff frequencies is programmable. This allows a dynamic selection of heart sounds for detection without a need for additional circuitry.
Cardiac sensing circuit 112 senses at least one cardiac signal indicative of cardiac electrical events that are needed for detection and measurements related to the heart sounds and/or their components. In one embodiment, the cardiac signal includes a surface ECG signal. In another embodiment, the cardiac signal includes an intracardiac ECG signal that is also referred to as an electrogram. Cardiac sensing circuit 112 includes a sensing amplifier to sense the cardiac signal, a cardiac events detector to detect the cardiac electrical events, and an event marker generator to label each detected cardiac electrical event with an event marker indicative of the timing and type of the detected cardiac electrical event. The detected electrical events include, by not limited to, selected atrial and ventricular contractions. The atrial and ventricular contractions include spontaneous contractions and artificially stimulated contractions.
Heart sound detector 130 detects the selected type heart sounds. In one embodiment, heart sound detector 130 detects the selected type heart sounds based on the acoustic sensor signal. In another embodiment, heart sound detector 130 detects the selected type heart sounds based on the acoustic sensor signal and the cardiac signal sensed by cardiac sensing circuit 112. In one embodiment, heart sound detector includes a gating module 132 and a detection module 134. Gating module 132 receives the acoustic sensor signal from sensor interface module 120 and the cardiac signal from cardiac sensing circuit 112. In one embodiment, the cardiac signal received by gating module 132 includes event makers representing the detected cardiac electrical events that allow or facilitate detection of the selected type heart sounds. Gating module 132 generates heart sound detection windows each timed for detection of one of the selected type heart sounds based on a time of occurrence of one of cardiac electrical events.
Following the detections of the selected type heart sounds by heart sound detector 130, parameter generator 140 makes measurements to generate parameter values of at least one predetermined parameter related to the detected heart sounds. In one embodiment, such a parameter value is measured from one detected heart sound. In another embodiment, the parameter value is calculated based on measurement of several detected heart sounds of the same type. The parameter values indicate the patient's hemodynamic performance, either directly or after further processing as discussed below. Parameter generator 140 includes a measurement module 150 to make measurements on the acoustic sensor signal. The measurements are timed with the detections of the selected type heart sounds. In one embodiment, measurement module 150 receives the acoustic sensor signal from heart sound detector 130 and the cardiac signal from cardiac sensing circuit 112.
Data acquisition enabler 118 controls the timing of overall data acquisition by timing the enablement of selected system components including at least one or more of acoustic sensor 110, sensor interface module 120, cardiac sensing circuit 112, heart sound detector 130, and parameter generator 140. In one embodiment, data acquisition enabler 118 enables the selected system components in response to an external command, such as given by the user. In another embodiment, data acquisition enabler 118 includes a data acquisition timer to enable the selected system components on a predetermined schedule. In one specific embodiment, the data acquisition timer enables the selected system components on a predetermined periodic basis. In another specific embodiment, if parameter generator 140 is unable to generate required parameter values on the predetermined schedule, for example, because the background noises exceeds the predetermined level when the selected system components are enabled, data acquisition enabler 118 modifies the predetermined schedule by introducing at least one delay to ensure that all the desired parameter values are obtained.
Parameter processor 160 processes the parameter values received from parameter generator 140. In one embodiment, parameter processor 160 includes a statistical processor 162, a trending analyzer 164, and an alert signal generator 166. Statistical processor 162 analyzes the parameter values generated by parameter generator 140 for a predetermined period of time. Trending analyzer 164 produces at least one trend related to the selected type heart sounds. The trend is a hemodynamic performance trend indicative of one or more cardiac conditions. In one embodiment, the trend is a plot of parameter values of one selected parameter related to the detected heart sounds over a predetermined period of time. In another embodiment, the trend is a plot of values derived for the parameter values as a result of the statistical process over the predetermined period of time. Alert signal generator 166 generates an alert signal indicative of a presence of the one or more cardiac conditions indicated by the at least one trend. In one embodiment, alert signal generator 166 includes a comparator. The comparator has a first input to receive the at least one trend, a second input representative of a predetermined threshold level, and an output indicative of the presence of the one or more clinical conditions when the at least one trend exceeds the predetermined threshold level. In one further embodiment, alert signal generator 166 includes a threshold generator that generates an adaptive threshold level based on at least one previously produced trend, such that the predetermined threshold is dynamically adjustable based on the patient's changing cardiac conditions.
Therapy circuit 170 includes, by way of example, but not by way of limitation, one or more of a pacing circuit, a defibrillation circuit, a cardiac resynchronization circuit, and a drug delivery circuit. It includes a therapy controller to execute a predetermined therapy algorithm that times therapy deliveries based on the processed cardiac signal and acoustic sensor signal. In one embodiment, the therapy controller receives at least one of selected parameter values generated by parameter generator 140, the at least one trend generated by trending analyzer 164, and the alert signal generated by alert signal generator 166, based on which it produces or adjusts one or more therapy parameters.
At 402, acoustic sensor 110 senses the acoustic energy related to cardiac mechanical activities and converts the acoustic energy to an acoustic sensor signal indicative heart sounds. In one embodiment, acoustic sensor 110 senses an acceleration indicative of the acoustic energy.
At 410, sensor interface module 410 processes the acoustic sensor signal to prepare for heart sound detection. In one embodiment, the acoustic sensor signal is amplified and filtered to increase its signal-to-noise ratio. Then, the acoustic sensor signal is digitized to the form of binary data. The digitized acoustic sensor signal is filtered to enhance indications of the selected type heart sounds. In one embodiment, the digitized acoustic sensor signal is filtered with at least one cutoff frequency determined based on the frequency spectrum of the selected type heart sounds.
At 420, heart sound detector 130 generates heart sound detection windows each timed for detecting one of the selected type heart sounds. The heart sound detection windows are each triggered by one of selected cardiac electrical events detected from the cardiac signal sensed at 404. In one embodiment, the selected cardiac electrical events include at least one of spontaneous or artificially stimulated atrial and ventricular contractions. In one embodiment, the selected cardiac electrical events are each represented by a predetermined event marker. In one specific embodiment, At 425, the selected type heart sounds are detected. In one embodiment, each of the selected type heart sounds is detected when the amplitude of the acoustic sensor signal exceeds a predetermined threshold level.
At 430, parameter generator 140 generates the parameter values of at least one parameter related to the detected heart sounds based on the acoustic sensor signal produced at 400 and/or the cardiac signal sensed at 404. Such parameter values include, by way of example, but not by way of limitation, one or more of (i) an amplitude associated with one or one selected type of the selected type heart sounds; (ii) a relative strength being differences between amplitudes associated with two or two selected types of the selected type heart sounds; (iii) a duration associated with one or one selected type of the selected type heart sounds; (iv) an electromechanical time intervals between one or one selected type of the selected type heart sounds and one or one type of selected type cardiac electrical events; (v) a mechanical time interval between two or two selected types of the selected type heart sounds; and (vi) a fundamental or harmonic frequency associated with one or one selected type of the selected type heart sounds. In one embodiment, parameter values related to S3 and/or S4 are measured and/or calculated for the purpose of monitoring ventricular diastolic hemodynamic performance. The parameter values of one or more of the following parameters are generated: (i) peak amplitude of S3; (ii) time of onset of S3 relative to onset of S2; (iii) duration of S3; (iv) fundamental frequency if S3; (v) time of occurrence of S3 relative to the subsequently adjacent atrial contraction; (vi) peak amplitude of S4; (vii) time interval between atrial contraction and the subsequently adjacent S4; (viii) fundamental frequency of S4; (ix) duration of S4; (x) time of occurrence of S4 relative to the subsequently adjacent ventricular contraction; and (xi) amplitude of S4 relative to amplitude of S3. In one embodiment, parameter generator 140 screens out noisy values of the parameter values measured at 435. Such noisy values include parameter values measured when the background noise level exceeds a predetermined threshold. In one embodiment, the patient's physical activities are sensed at 406 to produce an activity level signal indicative of the background noise level. In one specific embodiment, the activity level signal is derived from the same acoustic sensor signal from which the selected type heart sounds are detected. This is possible because the patient's physical activities are typically indicated with amplitudes that are distinctively higher than the amplitudes of the selected type heart sounds.
At 440, the parameter values are stored in memory circuit 146 or other storage medium. In one embodiment, system 100 uses the parameter values directly to control delivery of at least one therapy with at least one therapy parameter being a function of the parameter values. In another embodiment, the parameter values are further processed and analyzed by system 100 for monitoring, diagnosis, and/or therapy control purposes. In yet another embodiment, the stored parameter values are transferred to another system, such as a computer separated from system 100, for further processing and/or analysis.
At 450, parameter processor 160 statistically processes the parameter values. The statistical process includes analyzing the parameter values of the at least one parameter related to the detected heart sounds in relation to historical values of that parameter measured during a predetermined period of time. The outcome of the statistical process reveals changes in cardiac conditions reflected in the characteristics of the selected type heart sounds. In one embodiment, the outcome of the statistical process reveals changes in ventricular diastolic filling patterns during the predetermined period of time. In one specific embodiment, the predetermined period of time ranges from 1 day to 3 months.
At 460, parameter processor 160 produces at least one hemodynamic performance trend related to the selected type heart sounds. In one embodiment, parameter processor 160 produces the at least one trend based on the outcome of the statistical analysis. In one embodiment, one or more trends quantitatively present one or more ventricular diastolic filling pattern changes during a predetermined duration. In one embodiment, parameter processor 160 plots the parameter values of the at least one parameter related to the detected heart sounds versus time. In another embodiment, parameter processor 160 statistically processes the parameter values of the at least one parameter related to the detected heart sounds and plots the result. At 465, the one or more trends are analyzed for indication of cardiac conditions. In one embodiment, the values of each trend are compared to a predetermined threshold level, and a predefined cardiac condition is indicated when any value exceeds the predetermined threshold level. In one embodiment, the predetermined threshold level is determined based on at least one previously produced trend.
At 475, an alert signal is generated when a cardiac condition is indicated by the at least one hemodynamic performance trend at 470. The alert signal notifies the user of the cardiac condition that may need medical attention. In one embodiment, the cardiac condition requires delivery of a therapy. In another embodiment, the alert signal indicates a need for changing one or more therapy parameters.
In one embodiment, a therapy is delivered in response to the alert signal at 480. The therapy includes one or more of, for example, a pacing therapy, a defibrillation therapy, a cardiac resynchronization therapy, any other electrical stimulation therapy, and a drug therapy. The type of the therapy as therapy parameters are determined based on the at least one trend and/or selected values of the at least one parameter related to the detected heart sounds. In one specific embodiment, therapy circuit 170 delivers the therapy. In another embodiment, one or more therapy parameters are adjusted in response to the alert signal, and the new therapy parameters are determined based on the at least one trend and/or the selected values of the at least one parameter related to the detected heart sounds. In an alternative embodiment, the therapy delivery or the therapy parameter adjustments are not dependent on the alert signal. The at least one trend and/or the selected values of the at least one parameter related to the detected heart sounds directly determine the need for the therapy delivery or the therapy parameter adjustments.
Many embodiments combining the present method with available medical knowledge will be apparent to those of skill in the art. In one example, the fundamental frequency (also referred to as the pitch) of S3 is correlated to the stiffness of the left ventricular wall during the rapid filling phase of diastole. The wall stiffness is proportional to diastolic pressure in the left ventricle and to the thickness of the left ventricular wall. Therefore, an increase in the pitch of S3 is used to indicate one or more of an elevated left ventricular filling pressure and a thickened left ventricular wall. The elevation of the left ventricular filling pressure and/or the increase of the left ventricular wall thickness may reach a degree, represented by predetermined thresholds of S3 fundamental frequency, that requires an application of adjustment of a therapy. In another example, the amplitude of S3 is directly related to the rate of deceleration of blood flow into the left ventricle during the rapid filling phase of diastole. An increase in amplitude of S3 can be used to indicate an elevation of left atrial filling pressure, an increase in stiffness of the left ventricle, or both, which represent a restrictive filling pattern associated with heart failure. Therefore, the trend of S3 amplitude is useful in monitoring cardiac mechanical properties related to heart failure. In yet another example, the elevated filling pressures cause pulmonary edema. Thus, a physician determines the need of a drug therapy to relieve the elevated pressures based on one or more trends of parameters related to S3. These are a few examples, among many possible embodiments, illustrating how system 100 is used. In general, trends of any of the measured parameter values can be used individually, jointly, and/or in combination with other trends related to cardiac functions.
In one embodiment, programming implanted device 506 includes sending therapy parameters to implantable device 506. The therapy parameters provide an improved hemodynamic performance for a patient by delivering cardiac pacing pulses to the patient's heart. In one embodiment, the therapy parameters providing for the improved hemodynamic performance are determined by monitoring one or more ventricular diastolic hemodynamics as indicated by parameters related to heart sounds such as S3 and S4. Such parameters indicate the heart's mechanical activities and electromechanical association. In one specific embodiment, the acquisition of values of such parameters, the processing of the parameter values, and the subsequent determination of the therapy parameters are performed by system 100, as discussed above with reference to
External system 580 includes, among other things, an external antenna 676, an external telemetry module 678, a controller 682, and a user interface 684. In one embodiment, external telemetry module 678 and external antenna 676 are included in external device 585 to provide external system 580 with capability of communicating with implanted device 506 through telemetry link 570 and external device 585. Controller 682 controls telemetry operation of external system 580, processes signals received from implanted device 506 for presentation on user interface 684, and processes user commands entered through user interface 684 for transmission to implanted device 506. In one embodiment, one or more of the heart-sound related parameter values, trends, and alert signal, as discussed above, are acquired by system 100 and telemetered to external system 580 via telemetry link 570. Controller 682 executes a predetermined therapy control algorithm to determine whether to deliver a therapy or adjust one or more therapy parameters based on the one or more of the heart sound-related parameter values, trends, and alert signal.
In one embodiment, system 100 is completely within a hermetically sealed can that houses at least portions of implanted device 506. Housing acoustic sensor 110 in the can has the advantage of minimizing the background noise associated with physical movements of the sensor, especially when acoustic sensor 110 includes an accelerometer. In another embodiment, acoustic sensor 110 is attached to a lead of lead system 508. This allows disposition of acoustic sensor 110 in or near heart 501 such that it is near the mechanical activities being the sources of the heart sounds of interest.
To include substantially the whole system 100 within implanted device 506 provides for the advantage of a self-contained implantable cardiac rhythm management system incorporating heart-sound based therapy control. In one embodiment, the heart-sound based therapy control using system 100 is able to function without telemetry link 570, for example, when the patient is outside the range of the telemetry communication. Implanted device 506 determines, without the intervention of the user or controller 682, whether to deliver a therapy or adjust one or more therapy parameters based on the one or more of the parameter values, trends, and alert signal generated within itself by system 100.
In one embodiment, the parameter values are telemetered as they are generated. In another embodiment, parameter values are first stored in memory circuit 146. Data acquisition enabler 118 times transmission of the parameter values in response to a command from external device 580 or on a predetermined schedule.
To include parameter processor 160 in external system 580 avoids placing the demand of energy and circuit resources required by parameter processor 160 in implanted device 506, which is subject to design restraints including power and size limitations. The advantages also include the feasibility of updating parameter processing algorithms used by parameter processor 160 without the need of replacing implanted device 506.
It is to be understood that the above detailed description is intended to be illustrative, and not restrictive. For example, system 100 may be incorporated into any implanted or external medical device providing for ECG and heart sound monitoring. Other embodiments will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
This application is a continuation of and claims the benefit of priority under 35 U.S.C. § 120 to U.S. patent application Ser. No. 10/334,694, filed on Dec. 30, 2002, now issued as U.S. Pat. No. 7,972,275, which is hereby incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3773033 | Rodbard et al. | Nov 1973 | A |
3965339 | Mount et al. | Jun 1976 | A |
4094308 | Cormier | Jun 1978 | A |
4220160 | Kimball et al. | Sep 1980 | A |
4289141 | Cormier | Sep 1981 | A |
4428378 | Anderson et al. | Jan 1984 | A |
4428380 | Wong et al. | Jan 1984 | A |
4446872 | Marsoner et al. | May 1984 | A |
4548204 | Groch et al. | Oct 1985 | A |
4586514 | Schlager et al. | May 1986 | A |
4628939 | Little et al. | Dec 1986 | A |
4649930 | Groch et al. | Mar 1987 | A |
4674518 | Salo | Jun 1987 | A |
4686987 | Salo et al. | Aug 1987 | A |
4702253 | Nappholz et al. | Oct 1987 | A |
4712179 | Heimer | Dec 1987 | A |
4763646 | Lekholm | Aug 1988 | A |
4777960 | Berger et al. | Oct 1988 | A |
4796639 | Snow et al. | Jan 1989 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4825869 | Sasmor et al. | May 1989 | A |
4899751 | Cohen | Feb 1990 | A |
4905706 | Duff et al. | Mar 1990 | A |
4915113 | Holman | Apr 1990 | A |
4928688 | Mower | May 1990 | A |
4945909 | Fearnot et al. | Aug 1990 | A |
4967760 | Bennett et al. | Nov 1990 | A |
4981139 | Pfohl | Jan 1991 | A |
4989611 | Zanetti et al. | Feb 1991 | A |
5010889 | Bredesen et al. | Apr 1991 | A |
5012815 | Bennett, Jr. et al. | May 1991 | A |
5025809 | Johnson et al. | Jun 1991 | A |
5097831 | Lekholm | Mar 1992 | A |
5137019 | Pederson et al. | Aug 1992 | A |
5159932 | Zanetti et al. | Nov 1992 | A |
5179947 | Meyerson et al. | Jan 1993 | A |
5190035 | Salo et al. | Mar 1993 | A |
5218969 | Bredesen et al. | Jun 1993 | A |
5226413 | Bennett et al. | Jul 1993 | A |
5251626 | Nickolls et al. | Oct 1993 | A |
5282838 | Hauser et al. | Feb 1994 | A |
5284136 | Hauck et al. | Feb 1994 | A |
5292341 | Snell | Mar 1994 | A |
5301679 | Taylor | Apr 1994 | A |
5321618 | Gessman | Jun 1994 | A |
5334222 | Salo et al. | Aug 1994 | A |
5337752 | Reeves | Aug 1994 | A |
5365932 | Greenhut | Nov 1994 | A |
5372607 | Stone et al. | Dec 1994 | A |
5391190 | Pederson et al. | Feb 1995 | A |
5417717 | Salo et al. | May 1995 | A |
5421830 | Epstein et al. | Jun 1995 | A |
5472453 | Alt | Dec 1995 | A |
5487752 | Salo et al. | Jan 1996 | A |
5496361 | Moberg et al. | Mar 1996 | A |
5540727 | Tockman et al. | Jul 1996 | A |
5544661 | Davis et al. | Aug 1996 | A |
5549654 | Powell | Aug 1996 | A |
5554177 | Kieval et al. | Sep 1996 | A |
5584868 | Salo et al. | Dec 1996 | A |
5593431 | Sheldon | Jan 1997 | A |
5594638 | Iliff | Jan 1997 | A |
5607460 | Kroll et al. | Mar 1997 | A |
5630835 | Brownlee | May 1997 | A |
5674256 | Carlson | Oct 1997 | A |
5685317 | Sjostrom | Nov 1997 | A |
5687738 | Shapiro et al. | Nov 1997 | A |
5690690 | Nappholz et al. | Nov 1997 | A |
5697375 | Hickey | Dec 1997 | A |
5697959 | Poore | Dec 1997 | A |
5700283 | Salo | Dec 1997 | A |
5725562 | Sheldon | Mar 1998 | A |
5792195 | Carlson et al. | Aug 1998 | A |
5800473 | Faisandier | Sep 1998 | A |
5833623 | Mann et al. | Nov 1998 | A |
5836987 | Baumann et al. | Nov 1998 | A |
5860918 | Schradi et al. | Jan 1999 | A |
5860933 | Don Michael | Jan 1999 | A |
5891178 | Mann et al. | Apr 1999 | A |
5935081 | Kadhiresan | Aug 1999 | A |
5991657 | Kim | Nov 1999 | A |
5991661 | Park et al. | Nov 1999 | A |
6002777 | Grasfield et al. | Dec 1999 | A |
6015388 | Sackner et al. | Jan 2000 | A |
6016442 | Hsu et al. | Jan 2000 | A |
6022322 | Prutchi | Feb 2000 | A |
6026324 | Carlson | Feb 2000 | A |
6044297 | Sheldon et al. | Mar 2000 | A |
6044298 | Salo et al. | Mar 2000 | A |
6044299 | Nilsson | Mar 2000 | A |
6045513 | Stone et al. | Apr 2000 | A |
6053872 | Mohler | Apr 2000 | A |
6058329 | Salo et al. | May 2000 | A |
6064910 | Andersson et al. | May 2000 | A |
6077227 | Miesel | Jun 2000 | A |
6091990 | Hsu et al. | Jul 2000 | A |
6104949 | Pitts et al. | Aug 2000 | A |
6144880 | Ding et al. | Nov 2000 | A |
6152884 | Bjorgaas | Nov 2000 | A |
6161042 | Hartley et al. | Dec 2000 | A |
6168563 | Brown | Jan 2001 | B1 |
6190324 | Kieval et al. | Feb 2001 | B1 |
6193668 | Chassaing et al. | Feb 2001 | B1 |
6251126 | Ottenhoff et al. | Jun 2001 | B1 |
6264611 | Ishikawa et al. | Jul 2001 | B1 |
6269269 | Ottenhoff et al. | Jul 2001 | B1 |
6273856 | Sun et al. | Aug 2001 | B1 |
6275727 | Hopper et al. | Aug 2001 | B1 |
6278894 | Salo et al. | Aug 2001 | B1 |
6280409 | Stone et al. | Aug 2001 | B1 |
6298269 | Sweeney | Oct 2001 | B1 |
6312378 | Bardy | Nov 2001 | B1 |
6351672 | Park et al. | Feb 2002 | B1 |
6351673 | Ding et al. | Feb 2002 | B1 |
6360127 | Ding et al. | Mar 2002 | B1 |
6361522 | Scheiner et al. | Mar 2002 | B1 |
6366811 | Carlson | Apr 2002 | B1 |
6368283 | Xu et al. | Apr 2002 | B1 |
6370424 | Prutchi | Apr 2002 | B1 |
6383136 | Jordan | May 2002 | B1 |
6409675 | Turcott | Jun 2002 | B1 |
6411840 | Bardy | Jun 2002 | B1 |
6415033 | Halleck et al. | Jul 2002 | B1 |
6438407 | Ousdigian et al. | Aug 2002 | B1 |
6440082 | Joo et al. | Aug 2002 | B1 |
6459929 | Hopper et al. | Oct 2002 | B1 |
6466821 | Pianca et al. | Oct 2002 | B1 |
6477406 | Turcott | Nov 2002 | B1 |
6478746 | Chassaing et al. | Nov 2002 | B2 |
6480733 | Turcott | Nov 2002 | B1 |
6491639 | Turcott | Dec 2002 | B1 |
6520924 | Lee | Feb 2003 | B2 |
6527729 | Turcott | Mar 2003 | B1 |
6542775 | Ding et al. | Apr 2003 | B2 |
6575916 | Halleck et al. | Jun 2003 | B2 |
6584353 | Meyer | Jun 2003 | B2 |
6625493 | Kroll et al. | Sep 2003 | B2 |
6626842 | Oka | Sep 2003 | B2 |
6643548 | Mai et al. | Nov 2003 | B1 |
6650940 | Zhu et al. | Nov 2003 | B1 |
6658292 | Kroll et al. | Dec 2003 | B2 |
6665564 | Lincoln et al. | Dec 2003 | B2 |
6666826 | Salo et al. | Dec 2003 | B2 |
6684103 | Ding et al. | Jan 2004 | B2 |
6719701 | Lade | Apr 2004 | B2 |
6733464 | Olbrich et al. | May 2004 | B2 |
6752765 | Jensen et al. | Jun 2004 | B1 |
6792308 | Corbucci | Sep 2004 | B2 |
6795732 | Stadler et al. | Sep 2004 | B2 |
6810284 | Bradley | Oct 2004 | B1 |
6810287 | Zhu et al. | Oct 2004 | B2 |
6824519 | Narimatsu et al. | Nov 2004 | B2 |
6827690 | Bardy | Dec 2004 | B2 |
6830548 | Bonnet et al. | Dec 2004 | B2 |
6845263 | Kawaguchi | Jan 2005 | B2 |
6885889 | Chinchoy | Apr 2005 | B2 |
6913577 | Bardy | Jul 2005 | B2 |
6942622 | Turcott | Sep 2005 | B1 |
6961617 | Snell | Nov 2005 | B1 |
6963777 | Lincoln et al. | Nov 2005 | B2 |
6980851 | Zhu et al. | Dec 2005 | B2 |
7010342 | Galen et al. | Mar 2006 | B2 |
7043305 | Kenknight et al. | May 2006 | B2 |
7065397 | Galen et al. | Jun 2006 | B2 |
7072708 | Andersen et al. | Jul 2006 | B1 |
7074195 | Nelson et al. | Jul 2006 | B2 |
7079895 | Verbeek et al. | Jul 2006 | B2 |
7079896 | Park et al. | Jul 2006 | B1 |
7110804 | Baumer et al. | Sep 2006 | B2 |
7110817 | Yu et al. | Sep 2006 | B2 |
7113825 | Pastore et al. | Sep 2006 | B2 |
7115096 | Siejko et al. | Oct 2006 | B2 |
7123962 | Siejko et al. | Oct 2006 | B2 |
7127290 | Girouard et al. | Oct 2006 | B2 |
7139609 | Min et al. | Nov 2006 | B1 |
7158830 | Yu et al. | Jan 2007 | B2 |
7177685 | Lincoln et al. | Feb 2007 | B2 |
7206636 | Turcott | Apr 2007 | B1 |
7248923 | Maile et al. | Jul 2007 | B2 |
7366568 | Pastore et al. | Apr 2008 | B2 |
7387610 | Stahmann et al. | Jun 2008 | B2 |
7400928 | Hatlestad | Jul 2008 | B2 |
7404802 | Siejko et al. | Jul 2008 | B2 |
7424321 | Wariar et al. | Sep 2008 | B2 |
7431699 | Siejko et al. | Oct 2008 | B2 |
7480528 | Brockway et al. | Jan 2009 | B2 |
7493162 | Girouard et al. | Feb 2009 | B2 |
7559901 | Maile et al. | Jul 2009 | B2 |
7582061 | Li et al. | Sep 2009 | B2 |
7585279 | Carlson et al. | Sep 2009 | B2 |
7662101 | Lee et al. | Feb 2010 | B2 |
7662104 | Siejko et al. | Feb 2010 | B2 |
7668594 | Brockway et al. | Feb 2010 | B2 |
7713213 | Siejko et al. | May 2010 | B2 |
7736319 | Patangay et al. | Jun 2010 | B2 |
7751890 | McCabe et al. | Jul 2010 | B2 |
7780606 | Carlson et al. | Aug 2010 | B2 |
7844334 | Maile et al. | Nov 2010 | B2 |
7922669 | Zhang et al. | Apr 2011 | B2 |
7972275 | Siejko et al. | Jul 2011 | B2 |
8000780 | Wariar et al. | Aug 2011 | B2 |
8048001 | Patangay et al. | Nov 2011 | B2 |
20010007053 | Bardy | Jul 2001 | A1 |
20020001390 | Kawaguchi | Jan 2002 | A1 |
20020019586 | Teller et al. | Feb 2002 | A1 |
20020026103 | Norris et al. | Feb 2002 | A1 |
20020026223 | Riff et al. | Feb 2002 | A1 |
20020035337 | Oka | Mar 2002 | A1 |
20020072684 | Stearns | Jun 2002 | A1 |
20020082645 | Sweeney | Jun 2002 | A1 |
20020107450 | Ogura | Aug 2002 | A1 |
20020120298 | Kramer et al. | Aug 2002 | A1 |
20020128563 | Carlson et al. | Sep 2002 | A1 |
20020147401 | Oka | Oct 2002 | A1 |
20020151812 | Scheiner et al. | Oct 2002 | A1 |
20020151938 | Corbucci | Oct 2002 | A1 |
20030055352 | Hayek et al. | Mar 2003 | A1 |
20030055461 | Girouard et al. | Mar 2003 | A1 |
20030069608 | Sweeney | Apr 2003 | A1 |
20030072458 | Halleck et al. | Apr 2003 | A1 |
20030078624 | Carlson et al. | Apr 2003 | A1 |
20030093002 | Kuo | May 2003 | A1 |
20030093003 | Watrous et al. | May 2003 | A1 |
20030105496 | Yu et al. | Jun 2003 | A1 |
20030120159 | Mohler | Jun 2003 | A1 |
20030125774 | Salo | Jul 2003 | A1 |
20030144702 | Yu et al. | Jul 2003 | A1 |
20030144703 | Yu et al. | Jul 2003 | A1 |
20030158492 | Sheldon et al. | Aug 2003 | A1 |
20030158584 | Cates et al. | Aug 2003 | A1 |
20030171791 | KenKnight et al. | Sep 2003 | A1 |
20030176896 | Lincoln et al. | Sep 2003 | A1 |
20030191503 | Zhu et al. | Oct 2003 | A1 |
20030208240 | Pastore et al. | Nov 2003 | A1 |
20030216620 | Jain et al. | Nov 2003 | A1 |
20030229289 | Mohler | Dec 2003 | A1 |
20040024423 | Lincoln et al. | Feb 2004 | A1 |
20040039295 | Olbrich et al. | Feb 2004 | A1 |
20040039419 | Stickney et al. | Feb 2004 | A1 |
20040039420 | Jayne et al. | Feb 2004 | A1 |
20040064056 | Ogura | Apr 2004 | A1 |
20040078059 | Ding et al. | Apr 2004 | A1 |
20040078060 | Ding et al. | Apr 2004 | A1 |
20040102712 | Belalcazar et al. | May 2004 | A1 |
20040106960 | Siejko et al. | Jun 2004 | A1 |
20040106961 | Siejko et al. | Jun 2004 | A1 |
20040106962 | Mai et al. | Jun 2004 | A1 |
20040111040 | Ni et al. | Jun 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040127792 | Siejko et al. | Jul 2004 | A1 |
20040138572 | Thiagarajan | Jul 2004 | A1 |
20040167417 | Schulhauser et al. | Aug 2004 | A1 |
20040215264 | Van Bentem | Oct 2004 | A1 |
20040225332 | Gebhardt et al. | Nov 2004 | A1 |
20040236239 | Murray et al. | Nov 2004 | A1 |
20040243192 | Hepp et al. | Dec 2004 | A1 |
20040254481 | Brodnick | Dec 2004 | A1 |
20040267147 | Sullivan | Dec 2004 | A1 |
20040267148 | Arand et al. | Dec 2004 | A1 |
20050004485 | Crosby et al. | Jan 2005 | A1 |
20050027323 | Mulligan et al. | Feb 2005 | A1 |
20050033190 | Bauer | Feb 2005 | A1 |
20050060001 | Singhal et al. | Mar 2005 | A1 |
20050065448 | Stahmann et al. | Mar 2005 | A1 |
20050065556 | Reghabi et al. | Mar 2005 | A1 |
20050090870 | Hine et al. | Apr 2005 | A1 |
20050102001 | Maile et al. | May 2005 | A1 |
20050102002 | Salo et al. | May 2005 | A1 |
20050148896 | Siejko et al. | Jul 2005 | A1 |
20050148897 | Cho et al. | Jul 2005 | A1 |
20050149136 | Siejko et al. | Jul 2005 | A1 |
20050203579 | Sowelam et al. | Sep 2005 | A1 |
20050222515 | Polyshchuk et al. | Oct 2005 | A1 |
20050256542 | Pastore et al. | Nov 2005 | A1 |
20060020294 | Brockway et al. | Jan 2006 | A1 |
20060020295 | Brockway et al. | Jan 2006 | A1 |
20060025699 | Maile et al. | Feb 2006 | A1 |
20060030892 | Kadhiresan et al. | Feb 2006 | A1 |
20060161070 | Siejko et al. | Jul 2006 | A1 |
20060259087 | Baynham et al. | Nov 2006 | A1 |
20060259088 | Pastore et al. | Nov 2006 | A1 |
20060270939 | Wariar et al. | Nov 2006 | A1 |
20060282000 | Zhang et al. | Dec 2006 | A1 |
20070078491 | Siejko et al. | Apr 2007 | A1 |
20070150005 | Sih et al. | Jun 2007 | A1 |
20070239218 | Carlson et al. | Oct 2007 | A1 |
20080071315 | Baynham et al. | Mar 2008 | A1 |
20080103406 | Kameli | May 2008 | A1 |
20080119749 | Haro et al. | May 2008 | A1 |
20100099997 | Siejko et al. | Apr 2010 | A1 |
20100249863 | Carlson et al. | Sep 2010 | A1 |
20120271186 | Siejko et al. | Oct 2012 | A1 |
Number | Date | Country |
---|---|---|
0297675 | Jan 1989 | EP |
0709058 | May 1996 | EP |
1179317 | Feb 2002 | EP |
1247485 | Oct 2002 | EP |
61202653 | Sep 1986 | JP |
63-109103 | Jul 1988 | JP |
63-290544 | Nov 1988 | JP |
03015441 | Jan 1991 | JP |
04-082538 | Mar 1992 | JP |
06-277189 | Oct 1994 | JP |
2000-060846 | Feb 2000 | JP |
2000316825 | Nov 2000 | JP |
2001145606 | May 2001 | JP |
2004-081854 | Mar 2004 | JP |
4576236 | Nov 2010 | JP |
WO-0041765 | Jul 2000 | WO |
WO-0041766 | Jul 2000 | WO |
WO-0103575 | Jan 2001 | WO |
WO-0122885 | Apr 2001 | WO |
WO-0124876 | Apr 2001 | WO |
WO-0156651 | Aug 2001 | WO |
WO-0167948 | Sep 2001 | WO |
WO-2004012815 | Feb 2004 | WO |
WO-2004050178 | Jun 2004 | WO |
WO-2004060483 | Jul 2004 | WO |
WO-2004066825 | Aug 2004 | WO |
WO-2005074361 | Aug 2005 | WO |
WO-2005122902 | Dec 2005 | WO |
WO-2006028575 | Mar 2006 | WO |
WO-2006078757 | Jul 2006 | WO |
WO-2006127594 | Nov 2006 | WO |
Entry |
---|
U.S. Appl. No. 10/334,694, Advisory Action mailed Dec. 18, 2007, 3 pgs. |
U.S. Appl. No. 10/334,694, Advisory Action mailed Dec. 23, 2008, 3 pgs. |
U.S. Appl. No. 10/334,694, Final Office Action mailed Oct. 1, 2007, 13 pgs. |
U.S. Appl. No. 10/334,694, Final Office Action mailed Oct. 7, 2008, 14 pgs. |
U.S. Appl. No. 10/334,694, Final Office Action mailed Nov. 27, 2009, 13 pgs. |
U.S. Appl. No. 10/334,694, Non-Final Office Action mailed Mar. 18, 2009, 14 pgs. |
U.S. Appl. No. 10/334,694, Non-Final Office Action mailed Mar. 19, 2008, 15 pgs. |
U.S. Appl. No. 10/334,694, Non-Final Office Action mailed Apr. 20, 2007, 12 pgs. |
U.S. Appl. No. 10/334,694, Non-Final Office Action mailed Apr. 30, 2010, 13 pgs. |
U.S. Appl. No. 10/334,694, Non-Final Office Action mailed Nov. 27, 2006, 9 pgs. |
U.S. Appl. No. 10/334,694, Notice of Allowance mailed Mar. 4, 2011, 7 pgs. |
U.S. Appl. No. 10/334,694, Notice of Allowance mailed Oct. 5, 2010, 6 pgs. |
U.S. Appl. No. 10/334,694, Response filed Feb. 27, 2007 to Non-Final Office Action mailed Nov. 27, 2007, 20 pgs. |
U.S. Appl. No. 10/334,694, Response filed Mar. 1, 2010 to Final Office Action mailed Nov. 27, 2009, 21 pgs. |
U.S. Appl. No. 10/334,694, Response filed Jun. 19, 2008 to Non-Final Office Action mailed Mar. 19, 2008, 20 pgs. |
U.S. Appl. No. 10/334,694, Response filed Jul. 17, 2009 to Non Final Office Action mailed Mar. 18, 2009, 18 pgs. |
U.S. Appl. No. 10/334,694, Response filed Jul. 20, 2007 to Non-Final Office Action mailed Apr. 20, 2007, 18 pgs. |
U.S. Appl. No. 10/334,694, Response filed Jul. 27, 2010 to Non Final Office Action mailed Apr. 30, 2010, 19 pgs. |
U.S. Appl. No. 10/334,694, Response filed Dec. 3, 2007 to Final Office Action mailed Oct. 1, 2007, 21 pgs. |
U.S. Appl. No. 10/334,694, Response filed Dec. 8, 2008 to Final Office Action mailed Oct. 7, 2008, 18 pgs. |
European Serial Application No. 10158651.9, Extended European Search Report mailed on Jul. 29, 2010, 6 pgs. |
European Application Serial No. 03800278.8, Communication dated Oct. 17, 2007, 4 pgs. |
European Application Serial No. 03800278.8, Response filed Feb. 18, 2008 to Communication dated Oct. 17, 2007, 14 pgs. |
European Divisional Application Serial No. 10158651.9, Response filed Feb. 28, 2011 to EP Search Report mailed Jul. 29, 2010, 2. |
International Application Serial No. PCT/US03/41481, International Search Report mailed Jun. 4, 2004, 7 pgs. |
Japanese Application Serial No. 2004-565783, Amendment and Argument filed Feb. 5, 2010 to Office Action Mailed Nov. 11, 2009, (w/ English Translation of Amended Claims), 14 pgs. |
Japanese Application Serial No. 2004-565783, Notice of Allowance mailed Aug. 9, 2010, 2 pgs. |
Japanese Application Serial No. 2004-565783, Office Action mailed Mar. 11, 2010, (w/ English Translation), 4 pgs. |
Japanese Application Serial No. 2004-565783, Office Action mailed Nov. 11, 2009, (w/ English Translation), 4 pgs. |
Aaron, S. D, et al., “How accurate is spirometry at predicting restrictive pulmonary impairment?”, Chest, 115(3), XP002362629 ISSN: 0012-3692, (Mar. 1999), 869-873. |
Amende, I., “Hemodynamics in ischemia: diastolic phase”, Z. Kardiol., 73 Suppl 2, [Article in German With English Abstract], (1984), 127-33. |
Barbaro, V., et al., “A portable unit for remote monitoring of pacemaker patients”, Journal of Telemedicine and Telecare, 3(2), (1997), 96-102. |
Bulgrin, J. R, et al., “Comparison of Short-Time Fourier, Wavelet and Time-Domain Analyses of Intracardiac Sounds”, Biomedical Sciences Instrumentation, 29, (1993), 4 pgs. |
Collins, Sean, “Diagnostic Utility of an S3 in Dyspneic ED Patients”, Inovise Medical Inc, University of Cincinnati Medical Center, (2005), 6 pgs. |
Hutten, H., et al., “Cardiac Telemonitoring through the Linkage of Close-up Telemetry and Internet Transmission”, Institute for Electro-and Biomedical Technology, Technical University of Graz Inffeldgasse, 42, [Article in German with English Abstract], (1997), 67-69. |
Leatham, A, “Splitting of the First and Second Heart Sounds”, Lancet, 267 (6839), (Sep. 25, 1954), 607-614. |
Marcus, G. M., et al., “Association Between Phonocardiographic Third and Fourth Heart Sounds and Objective Measures of Left Ventricular Function”, JAMA, 293(18), (May 11, 2005), 2238-44. |
Obaidat, M. S, et al., “Performance of the Short-Time Fourier Transform and Wavelet Transform to Phonocardiogram Signal Analysis”, Proceedings of the 1992 ACM/SIGAPP Symposium on Applied Computing ACM, Applied Computing: Technological Challenges of the 1990s, (1992), 856-862. |
Smith, Damon, et al., “Influence of the Aortic Component of the Second Heart Sound on Left Ventricular Maximal Negative dP/dt in the Dog”, Am. J. Cardiol., 55: 205, (1985), 205-209. |
Wood, J. C, et al., “Time-Frequency Transforms: A New Approach to First Heart Sound Frequency Dynamics”, IEEE Transactions on Biomedical Engineering, 39 (7), IEEE Service Center, US, (Jul. 1, 1992), 730-740. |
European Application Serial No. 10158651.9, Examination Notification Art. 94(3) mailed Jul. 20, 2011, 5 pgs. |
European Application Serial No. 10158651.9, Response filed Nov. 29, 2011 to Office Action mailed Jul. 20, 2011, 10 pgs. |
Japanese Application Serial No. 2004-565783, Amendment and Response filed Jun. 2, 2010 to Office Action mailed Mar. 11, 2010, (w/ English Translation of Amended Claims), 14 pgs. |
Number | Date | Country | |
---|---|---|---|
20110098588 A1 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10334694 | Dec 2002 | US |
Child | 12985055 | US |